Given their glucose-lowering effects, GLP-1s have become standard of care for type 2 diabetes, supplanting other medication classes such as sulfonylureas.2 In 2023, GLP-1s represented 63% of diabetes spend, up from 38% in 2020.2 While diabetes GLP-1s will continue to account for a greater portion of spend compared to obesity, costs related to GLP-1s prescribed for obesity are expected to grow at a faster rate over the next 3 years
The molecular mechanism of tamoxifen activity in macrophages was initially associated with the activation of PKC and transcription factors, such as GR, PPARy and STAT1 (Komi et al., 2001
After this point, you may begin to see a gradual decline in potency, which can skew your research results
Does higher dosing improve outcomes
New hope for patients with various medical conditions